has dermal delivery technology and agreement with Roche and others. Roche can combine 10 compounds to HALO technology, also choose 4-5 compounds and running trials on it.
Roche this wednesday announced it will invest 190 million euros to implement technology to use HALO delivery in their manufacturing plants.
JANUARY 20, 2010, 1:07 A.M. ET.Roche Invests CHF190M In Herceptin Formulation Admin Device
ZURICH (Dow Jones)--Swiss pharmaceutical company Roche Holding AG (ROG.VX) said Wednesday, it is investing about 190 million Swiss francs ($183 million) at its production sites in Kaiseraugst, Switzerland, and Mannheim, Germany.
MAIN FACTS
-The production line in Kaiseraugst will provide the supply for clinical studies and market launch, and a full scale automated production line in Mannheim will deliver commercial supply to markets.
-The new infusion-free device will deliver an innovative Herceptin, or trastuzumab, formulation developed with Halozyme Therapeutics's "Enhanze" technology.
-This Herceptin formulation together with the ready-to-use administration device allows for injection of larger volumes of medicines into the tissue under the skin. Medicines which are currently administered by infusion in a hospital could therefore be self-administered via a subcutaneous injection.
PARD (2.56) up 21% on another red day in the market. Very well done here as we alerted and I bought at $2.12 prior to the conference! Let's hope it continues. $heff
Market Data 
Markets 
AI
